Indications

Indication	Clinical Context
Indeterminate hepatic lesion	Establish benign vs. malignant diagnosis when imaging features are not conclusive; not required for classic LI-RADS-5 HCC
Metastatic disease with unknown primary	Hepatic metastasis requiring tissue to determine primary cell of origin or guide systemic therapy selection
Tissue for molecular profiling	Biomarker, genomic, or genotype analysis to guide targeted therapy or clinical trial eligibility
Diffuse parenchymal disease	Cirrhosis staging, unexplained transaminitis, suspected hemochromatosis, autoimmune hepatitis, or other infiltrative processes
Hepatic infection	Known or suspected pyogenic or amebic abscess; atypical infection not responding to empiric treatment

Contraindications

Type	Contraindication
Absolute	Uncorrectable coagulopathy; no safe access window to the target; hemodynamic instability; suspected hepatic hemangioma (biopsy contraindicated)
Relative	INR >1.8 without correction; platelets <50,000; significant ascites (consider TJLB); prior hepatic encephalopathy; biliary obstruction along planned tract

High-risk patient planning: In patients with cirrhosis, INR does not reliably predict post-biopsy bleeding — thromboelastography (TEG/ROTEM) may better reflect true hemostatic balance. For INR >2.0 or significant ascites, transjugular liver biopsy (TJLB) is strongly preferred as any hemorrhage remains intravascular. TJLB also permits simultaneous hepatic venous pressure gradient (HVPG) measurement.

Relevant Anatomy

Access Routes

The subcostal approach is preferred for the majority of hepatic targets — the needle is advanced below the right costal margin directed superiorly toward the target, entirely avoiding the pleural space. For dome lesions in segments 7 and 8, the intercostal approach is required — pass between ribs along the superior rib margin to avoid the intercostal neurovascular bundle; be aware that dome access often requires supra-diaphragmatic entry with the risk of pleural transgression. The right pleura reflects at the 8th rib anterolaterally and 10th rib posterolaterally.

For left lobe targets, an epigastric approach is used — confirm the stomach and gastric vessels are not in the trajectory by reviewing imaging and with real-time ultrasound before advancing. For all approaches, the needle trajectory should include a segment of normal hepatic parenchyma between the capsule and the target to provide tamponade on withdrawal.

Danger Structures

Identify the portal vein and hepatic veins with Doppler before needle placement — major vascular injury is the most serious technical complication. The gallbladder must be identified and excluded from the trajectory — inadvertent transgression causes biliary peritonitis. The major bile ducts (right and left hepatic ducts, common hepatic duct) should be visualized on pre-procedure imaging and avoided, particularly for central right lobe targets.

Pre-Procedure Checklist

Imaging Review

Contrast-enhanced CT or MRI for lesion characterization, access route planning, and identification of vascular structures
Doppler ultrasound to assess hepatic vein and portal vein patency
Confirm lesion is not a hemangioma — biopsy is absolutely contraindicated; typical hemangiomas do not require biopsy

Labs

PT/INR, platelet count, hemoglobin; type and screen for high-risk cases
SIR Category 3: target INR <1.8; platelets >50,000 (ideally >100,000 in cirrhotic patients)
Chronic liver disease: vitamin K 10 mg slow IV if INR >2.5; cryoprecipitate if fibrinogen <100 mg/dL; consider TEG/ROTEM for hemostatic assessment
Hold anticoagulation per SIR Category 3 guidelines; high-thrombotic-risk patients may need bridging — multidisciplinary discussion required

Consent Considerations

Discuss with the patient: hemorrhage (most common complication; ~0.2–0.5% major requiring transfusion or embolization), biloma or bile leak, biliary fistula, pneumothorax (intercostal or dome approach), hemobilia, infection, tumor seeding (extremely rare with coaxial technique), and procedure-related death (<0.01%).

Procedure Overview

The following is a high-level summary. Full step-by-step technique, equipment selection, and troubleshooting are available in RadCall Pro.

Guidance modality selection — ultrasound is first-line (real-time, Doppler, no radiation); CT for deep, dome, or occult lesions; contrast-enhanced US (CEUS) for isoechoic lesions
Patient positioning and time-out — supine with right arm overhead for most cases; confirm patient identity, target, and laterality; sterile prep and drape
Needle trajectory planning — shortest safe path including normal liver parenchyma; subcostal preferred; Doppler to confirm no large vessel in path
Local anesthesia — infiltrate from skin to hepatic capsule; allow extra time at the capsule before advancing
Coaxial introducer placement — advance to target under real-time US or stepwise CT; ask patient to breath-hold in expiration before capsule crossing to reduce liver excursion
Sampling passes — FNA (if planned) and core biopsy through the coaxial introducer; obtain at least 2–3 cores; target the peripheral viable rim — avoid central necrosis
Tract management and withdrawal — consider tract embolization with gelatin foam on withdrawal in cirrhotic patients or for larger tracts; apply sterile dressing
Specimen distribution — formalin for histology and IHC; saline or RPMI for molecular profiling, lymphoma, or infection workup; confirm containers with pathology in advance

Complications

Complication	Rate	Recognition & Management
Hemorrhage	~1–3% minor; ~0.2–0.5% major	Post-procedure observation; CT for pain or hemodynamic change; angiography and embolization for active arterial bleeding
Hemobilia	Rare	Arteriobiliary fistula; presents with Quincke's triad (RUQ pain, jaundice, GI bleeding); angiography and embolization; ERCP for biliary decompression
Biloma / bile leak	0.1–0.5%	Observation if small and asymptomatic; IR drainage with antibiotic coverage if symptomatic or enlarging
Pneumothorax	Rare (intercostal approach)	Small — observation; significant — chest tube placement; avoided by subcostal approach when feasible
Tumor seeding	<0.01% with coaxial technique	Higher risk with repeat single-needle FNA of HCC without coaxial system; coaxial technique is preferred for this reason
Death	<0.01%	Overall major complication rate <1%; higher in cirrhotic and anticoagulated patients

Post-Procedure Care

Monitoring

Minimum 1-hour observation for uncomplicated cases; 4–6 hours for high-risk patients (cirrhosis, coagulopathy, complex access)
Vitals every 30 minutes for 2 hours, then every 1 hour
RUQ or right shoulder pain is common and usually pleuritic (normal); sudden severe pain warrants urgent evaluation for hemorrhage
CBC at 4 hours for cirrhotic or anticoagulated patients

Discharge

Discharge criteria: stable vitals, tolerating oral intake, pain controlled, no signs of hemorrhage
No strenuous activity for 24–48 hours
Return to ED for severe pain, hypotension, fever, jaundice, or GI bleeding
Pathology results in 2–5 business days; molecular profiling may take additional 1–2 weeks

When to Escalate

Hemodynamic instability post-biopsy — urgent CT with contrast to assess for hepatic hemorrhage; emergent angiography and embolization for active arterial bleeding
Quincke's triad (RUQ pain, jaundice, GI bleeding) — suspect hemobilia; angiography for arteriobiliary fistula; ERCP for biliary decompression if needed
Expanding biloma — IR drainage; antibiotic coverage; hepatobiliary surgery consultation if peritonitis develops
Coagulopathy not correctable to safe threshold — escalate to transjugular liver biopsy (TJLB) which is intravascular and avoids the risk of intraperitoneal hemorrhage

References

AASLD Practice Guidance: Evaluation of Liver Biopsy. 2023.
Rockey DC, et al. Liver biopsy. Hepatology. 2009;49(3):1017–1044.
Midia M, et al. Predictors of bleeding complications following percutaneous image-guided liver biopsy. Diagn Interv Radiol. 2019;25(1):71–80.

CT-Guided Liver Biopsy